Compare Stocks: OPT, STOK, AUPH, and ZBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$15.29 -1.2%	$15.91	$10.34 ▼ $19.25	$2.06B	1.42	1.15 million shs	996,713 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
STOK Stoke Therapeutics	$32.13 +2.8%	$30.75	$17.95 ▼ $40.22	$2.02B	1.2	816,472 shs	444,653 shs
ZBIO Zenas BioPharma	$30.50 +3.4%	$27.21	$13.50 ▼ $44.60	$1.92B	-1.03	700,358 shs	490,106 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-2.40%	-3.07%	-0.83%	+26.08%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
STOK Stoke Therapeutics	0.00%	-4.40%	+7.64%	+7.72%	+71.72%
ZBIO Zenas BioPharma	0.00%	-9.00%	-0.07%	+74.51%	+75.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$15.29 -1.2%	$15.91	$10.34 ▼ $19.25	$2.06B	1.42	1.15 million shs	996,713 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
STOK Stoke Therapeutics	$32.13 +2.8%	$30.75	$17.95 ▼ $40.22	$2.02B	1.2	816,472 shs	444,653 shs
ZBIO Zenas BioPharma	$30.50 +3.4%	$27.21	$13.50 ▼ $44.60	$1.92B	-1.03	700,358 shs	490,106 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-2.40%	-3.07%	-0.83%	+26.08%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
STOK Stoke Therapeutics	0.00%	-4.40%	+7.64%	+7.72%	+71.72%
ZBIO Zenas BioPharma	0.00%	-9.00%	-0.07%	+74.51%	+75.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.17	Hold	$17.67	15.54% Upside
OPT Opthea	1.00	Sell	N/A	N/A
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	33.83% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$45.71	49.88% Upside

Current Analyst Ratings Breakdown

Latest OPT, STOK, AUPH, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $32.00
8/14/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
8/14/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/4/2026	STOK Stoke Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/4/2026	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$38.00 ➝ $40.00
8/4/2026	STOK Stoke Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $58.00
8/4/2026	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
7/21/2026	AUPH Aurinia Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$311.51M	6.53	$1.00 per share	15.27	$4.41 per share	3.47
OPT Opthea	$25K	20,993.46	N/A	N/A	($1.31) per share	-2.60
STOK Stoke Therapeutics	$184.42M	11.24	N/A	N/A	$6.17 per share	5.21
ZBIO Zenas BioPharma	$10M	198.80	N/A	N/A	$4.51 per share	6.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	6.68	17.78	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
OPT Opthea	-$162.79M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	N/A

Latest OPT, STOK, AUPH, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
OPT Opthea	N/A	0.22	0.22
STOK Stoke Therapeutics	N/A	7.69	7.69
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
OPT Opthea	55.95%
STOK Stoke Therapeutics	N/A
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	10.40%
OPT Opthea	3.20%
STOK Stoke Therapeutics	9.60%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
OPT Opthea	8	153.91 million	165.53 million	Not Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable
ZBIO Zenas BioPharma	N/A	65.18 million	50.84 million	N/A

OPT, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

Zenas BioPharma's (ZBIO) "Buy" Rating Reiterated at Guggenheim

August 17 at 1:18 AM | americanbankingnews.com

Zenas BioPharma's (ZBIO) "Outperform" Rating Reiterated at Wedbush

August 17 at 1:18 AM | americanbankingnews.com

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO

August 15 at 6:31 AM | marketbeat.com

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

August 14 at 9:41 AM | marketbeat.com

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

August 14 at 9:17 AM | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 13, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

August 13, 2026 | marketbeat.com

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Zenas BioPharma (ZBIO) Expected to Post Quarterly Earnings on Tuesday

August 9, 2026 | americanbankingnews.com

Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts

July 29, 2026 | marketbeat.com

Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

July 28, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC

July 24, 2026 | marketbeat.com

SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO

July 24, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO

July 22, 2026 | marketbeat.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

July 14, 2026 | seekingalpha.com

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

July 11, 2026 | finance.yahoo.com

Zenas BioPharma Inc ZBIO

June 27, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$15.29 -0.18 (-1.16%)

As of 04:00 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Opthea NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Stoke Therapeutics NASDAQ:STOK

$32.13 +0.86 (+2.75%)

As of 04:00 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$30.50 +0.99 (+3.35%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, STOK, AUPH, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, STOK, AUPH, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

Opthea NASDAQ:OPT

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, STOK, AUPH, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, STOK, AUPH, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

Opthea NASDAQ:OPT

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools